Bioresorbable Coronary Scaffold Thrombosis: Multicenter Comprehensive Analysis of Clinical Presentation, Mechanisms, and Predictors

详细信息    查看全文

• 作者：Serban Puricel ; MD^a ; Florim Cuculi ; MD^b ; Melissa Weissner ; MTA^c ; Axel Schmermund ; MD^d ; Peiman Jamshidi ; MD^b ; Tobias Nyffenegger ; MD^b ; Harald Binder ; PhD^e ; Holger Eggebrecht ; MD^d ; Thomas Mü ; nzel ; MD^c ; Stephane Cook ; MD^a ; Tommaso Gori ; Dott Med Chir ; PhD^c ; ^{tommaso.gori@unimedizin-mainz.de" class="auth_mail" title="E-mail the corresponding author}
• 关键词：bioresorbable scaffold ; stent thrombosis
• 刊名：Journal of the American College of Cardiology
• 出版年：2016
• 出版时间：1 March 2016
• 年：2016
• 卷：67
• 期：8
• 页码：921-931
• 全文大小：1266 K

文摘

Recent reports suggest an elevated incidence of bioresorbable vascular scaffold (BVS) thrombosis (scaffold thrombosis [ScT]).

Objectives

This study investigated occurrence rates, clinical and angiographic characteristics, and possible mechanisms of ScT in all-comer patients undergoing BVS implantation at 2 German and 2 Swiss hospitals.

Methods

A total of 1,305 consecutive patients (mean age 64 years, 78% male) who received 1,870 BVS (mean 1.4 ± 0.8 BVS/patient) were enrolled. Clinical/procedural characteristics, mortality, and ScT data at 485 days (range 312 to 652 days) were examined.

Results

ScT occurred in 42 patients. The incidence of probable and definite ScT was 1.8% at 30 days and 3.0% at 12 months, without differences among centers (p = 0.60). A total of 22 (52%) ScTs presented as ST-segment elevation myocardial infarction and 6 (17%) as sudden cardiac death. In multivariable analysis, ostial lesions (p = 0.049) and impaired left ventricular ejection fraction (p = 0.019) were independently associated with ScT. Nine (21%) of the ScTs occurred in patients who had suspended dual antiplatelet therapy, in 6 cases prematurely. Lower post-procedural minimum lumen and reference vessel diameters were hallmarks of ScT (all p < 0.0001). The risk of ScT appeared to rapidly increase for post-procedural minimum lumen diameters below 2.4 mm (for the 2.5- to 3.0-mm BVS) and 2.8 mm (for the 3.5-mm BVS). When a BVS-specific implantation strategy was implemented, 12-month ScT rates fell from 3.3% to 1.0%, an effect that remained significant when adjusted for multivariable propensity score (p = 0.012; hazard ratio: 0.19; 95% confidence interval: 0.05 to 0.70).

Conclusions

The 12-month incidence of ScT reached 3% and could be significantly reduced when an optimized implantation strategy was employed. (retrospective multicentric registry and Mainz Intracoronary Database. The Coronary Slow-flow and Microvascular Diseases Registry [MICAT]; NCT02180178)